
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Stressed out?
Looking for solutions for efficiency and balance? We can help.
This guide book brings you the best of Physicians Practice to help you:
Choose from three ordering options:




